Stifel Nicolaus Issues Pessimistic Forecast for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN) had its price objective lowered by Stifel Nicolaus from $72.00 to $60.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 46.67% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Robert W. Baird boosted their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday. StockNews.com raised LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. Finally, Needham & Company LLC dropped their price target on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, LivaNova has an average rating of “Buy” and a consensus target price of $65.33.

LivaNova Price Performance

LivaNova stock opened at $40.91 on Wednesday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.22 billion, a P/E ratio of 97.26 and a beta of 1.00. The business has a 50-day moving average of $47.78 and a 200-day moving average of $49.62. LivaNova has a 1 year low of $40.51 and a 1 year high of $64.47.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is owned by insiders.

Hedge Funds Weigh In On LivaNova

Several hedge funds have recently made changes to their positions in the business. State of Alaska Department of Revenue lifted its position in shares of LivaNova by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares in the last quarter. abrdn plc lifted its position in LivaNova by 43.8% during the 3rd quarter. abrdn plc now owns 232,025 shares of the company’s stock worth $12,191,000 after buying an additional 70,618 shares in the last quarter. Emerald Advisers LLC lifted its position in LivaNova by 2.1% during the 3rd quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock worth $36,542,000 after buying an additional 14,302 shares in the last quarter. Atria Investments Inc boosted its stake in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after buying an additional 331 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D grew its holdings in shares of LivaNova by 38.3% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock valued at $2,235,000 after acquiring an additional 11,782 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.